Literature DB >> 8940234

Changes in endotoxin-induced cytokine production by whole blood after in vivo exposure of normal humans to endotoxin.

T van der Poll1, S M Coyle, L L Moldawer, S F Lowry.   

Abstract

Whole blood of 6 healthy subjects, who were intravenously injected with lipopolysaccharide (LPS, 2 ng/kg), was stimulated ex vivo with LPS (10 ng/mL). Three and 6 h after injection of LPS, whole blood produced less tumor necrosis factor-alpha (TNF), interleukin (IL)-1beta, IL-6, and IL-10 (all P < .05). By contrast, the production of IL-1 receptor antagonist was enhanced after LPS injection (P < .05). Plasma obtained 2 h, but not 1 h, after in vivo administration of LPS showed a dose-dependent inhibition of TNF, IL-1beta, and IL-6 production by LPS-stimulated whole blood from 6 other healthy donors not previously exposed to LPS, while the production of IL-10 and IL-1 receptor antagonist were not or were marginally influenced. LPS tolerance represents a purposeful adaptation of the host, rather than a generalized hyporesponsiveness, and is at least partly mediated by soluble factors produced within 2 h after previous exposure to LPS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8940234     DOI: 10.1093/infdis/174.6.1356

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

Review 1.  Gene-specific epigenetic regulation in serious infections with systemic inflammation.

Authors:  Charles E McCall; Barbara Yoza; Tiefu Liu; Mohamed El Gazzar
Journal:  J Innate Immun       Date:  2010-04-27       Impact factor: 7.349

Review 2.  Gene silencing in severe systemic inflammation.

Authors:  Charles E McCall; Barbara K Yoza
Journal:  Am J Respir Crit Care Med       Date:  2007-01-25       Impact factor: 21.405

3.  NETWORKS, BIOLOGY AND SYSTEMS ENGINEERING: A CASE STUDY IN INFLAMMATION.

Authors:  P T Foteinou; E Yang; I P Androulakis
Journal:  Comput Chem Eng       Date:  2009-12-10       Impact factor: 3.845

4.  Minimally invasive surgery induces endotoxin-tolerance in the absence of detectable endotoxemia.

Authors:  L C Lemaire; T van der Poll; J J van Lanschot; E Endert; W A Buurman; S J van Deventer; D J Gouma
Journal:  J Clin Immunol       Date:  1998-11       Impact factor: 8.317

5.  Expression of tumour necrosis factor receptor and Toll-like receptor 2 and 4 on peripheral blood leucocytes of human volunteers after endotoxin challenge: a comparison of flow cytometric light scatter and immunofluorescence gating.

Authors:  X Wittebole; S M Coyle; A Kumar; M Goshima; S F Lowry; S E Calvano
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

6.  Diminished monocyte function in microfilaremic patients with lymphatic filariasis and its relationship to altered lymphoproliferative responses.

Authors:  B Sasisekhar; M Aparna; D J Augustin; P Kaliraj; S K Kar; T B Nutman; R B Narayanan
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

Review 7.  Molecular regulation of hepatic dendritic cell function and its relation to liver transplant outcome.

Authors:  Tina L Sumpter; John G Lunz; A Jake Demetris; Angus W Thomson
Journal:  Transplantation       Date:  2009-08-15       Impact factor: 4.939

8.  Reduced Th1, but not Th2, cytokine production by lymphocytes after in vivo exposure of healthy subjects to endotoxin.

Authors:  F N Lauw; T ten Hove; P E Dekkers; E de Jonge; S J van Deventer; T van Der Poll
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

9.  Vitamin D-binding protein deficiency in mice decreases systemic and select tissue levels of inflammatory cytokines in a murine model of acute muscle injury.

Authors:  Richard R Kew; Tahmineh Tabrizian; James A Vosswinkel; James E Davis; Randeep S Jawa
Journal:  J Trauma Acute Care Surg       Date:  2018-06       Impact factor: 3.313

10.  Modeling endotoxin-induced systemic inflammation using an indirect response approach.

Authors:  P T Foteinou; S E Calvano; S F Lowry; I P Androulakis
Journal:  Math Biosci       Date:  2008-09-20       Impact factor: 2.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.